Physician

Myron Emil Bednar, M.D.

According to 2025 Medicare claims, Myron Bednar, M.D. (NPI: 1235127622) practices hematology in the Newark, NJ market, with the plurality of this provider's patient population coming from Hunterdon, NJ. This provider's primary affiliated billing organization is HUNTERDON HEMATOLOGY ONCOLOGY, LLC (NPI: 1154319531; TIN: 020543270) and primary practice location at 08822-4603.

Bednar's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 767 traditional Medicare patients, billed 393,401 HCPCS/CPT codes, and received $5,094,182 in Medicare payments. The top billing code was 99213 (Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more). Part D data shows 2,792 prescription claims across 369 beneficiaries totaling $14,019,591 in drug costs, led by Revlimid (Lenalidomide). DME data shows 12 claims. Open Payments data shows 126 records totaling $29,957. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $2,637,679 to $14,019,591. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $8,866 to $1,019.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	744	336,557	$3,675,037
2016	867	356,635	$5,222,817
2017	954	323,366	$5,298,542
2018	800	338,640	$5,742,547
2019	736	308,772	$5,659,320
2020	651	291,798	$5,627,646
2021	684	317,677	$5,734,384
2022	616	371,647	$5,602,578
2023	639	373,747	$4,752,909
2024	767	393,401	$5,094,182

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	271	2,108	$2,637,679
2016	290	2,043	$3,125,650
2017	280	2,227	$4,619,166
2018	294	2,562	$6,548,831
2019	326	2,739	$7,461,100
2020	343	2,906	$9,335,827
2021	359	2,692	$10,672,909
2022	346	2,648	$11,573,678
2023	307	2,435	$12,089,351
2024	369	2,792	$14,019,591

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	151	$35,075
2016	N/R	189	$20,312
2017	N/R	36	$11,657
2018	N/R	42	$4,977
2019	N/R	71	$6,793
2020	N/R	126	$9,201
2021	13	108	$6,559
2022	12	63	$2,092
2023	N/R	53	$4,041
2024	N/R	12	$110

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	408	1,146	$73
80053	Blood test, comprehensive group of blood chemicals	480	1,338	$10
36415	Insertion of needle into vein for collection of blood sample	422	867	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	572	2,516	$8
83615	Lactate dehydrogenase (enzyme) level	470	1,319	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	63	1,757	$1,235,273
Lenalidomide	Lenalidomide	66	1,799	$897,537
Erleada	Apalutamide	63	1,890	$888,712
Calquence	Acalabrutinib Maleate	55	1,650	$830,859
Jakafi	Ruxolitinib Phosphate	42	1,260	$716,747

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E1038	Transport chair, adult size, patient weight capacity up to and including 300 pounds	Y	N/R	12	$110

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	120	$4,783	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	6	$25,174	Genentech, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Myron Emil Bednar, M.D.?

Tedicare shows public-source Medicare data for Myron Emil Bednar, M.D. (NPI 1235127622), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Myron Emil Bednar, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Myron Emil Bednar, M.D.?

Myron Emil Bednar, M.D. is linked to HUNTERDON HEMATOLOGY ONCOLOGY, LLC (billing NPI 1154319531) in the available physician profile data.

Does Myron Emil Bednar, M.D. have Open Payments data?

Myron Emil Bednar, M.D. has 126 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.